Evidence map›Paper›PMID 41694495›Full record

ArticleWorld journal of gastroenterology2026

Anatomical laterality of primary intestinal diffuse large B-cell lymphoma independently stratifies survival: New prognostic nomogram incorporating tumor location.

Rui-Xin Zeng, Cai-Qin Wang, Hang Yang, Peng Sun, Pan-Pan Liu, Lin-Chuan Wei, Ting-Ting Chen, Zhao Wang, He Huang, Zhi-Ming Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rui-Xin ZengDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Cai-Qin WangDepartment of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha 410013, Hunan Province, China.
Hang YangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Peng SunDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Pan-Pan LiuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Lin-Chuan WeiZhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China.
Ting-Ting ChenDepartment of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen 518100, Guangdong Province, China.
Zhao WangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
He HuangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Zhi-Ming LiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Xiao-Peng TianDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Yu WangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China. wangyu@sysucc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary intestinal (PI) diffuse large B-cell lymphoma (DLBCL) represents a biologically and clinically heterogeneous subtype of extranodal lymphoma. The international prognostic index (IPI) was originally developed for predominantly nodal DLBCL (N-DLBCL) and inadequately reflected site-specific risk within the intestine. Prompted by colorectal carcinoma where primary tumor laterality (left

aimTo investigate whether intestinal laterality influences survival in PI-DLBCL and construct a location-integrated prognostic nomogram.

methodsWe retrospectively analyzed 3832 PI-DLBCL patients (SEER 2002-2021) and externally validated in 107 patients (Sun Yat-sen University Cancer Center 2014-2024). A prognostic nomogram integrating age, Ann Arbor stage, chemotherapy, surgery, and tumor sidedness (left

resultsLeft-sided PI-DLBCL was independently associated with inferior overall survival (OS) (hazard ratio = 1.15,

conclusionIntestinal laterality is an independent, clinically actionable determinant of survival in PI-DLBCL. The proposed nomogram provides individualized survival prediction and risk stratification and showed higher discrimination than the IPI, supporting the incorporation of tumor anatomical location into prognostic assessment and risk-adapted management.

Indexed as

Intestinal NeoplasmsLymphoma, Large B-Cell, DiffuseNomogramsAdultAgedAged, 80 and overColon, TransverseFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRisk AssessmentSEER ProgramExternal validationPrimary intestinal diffuse large B-cell lymphomaPrognostic modelRisk factorsSEER

Identifiers

PMID41694495
PMCPMC12897904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.